[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","o7by3aenjuppy7f3mi1rbavaa","revision",2,"title","Legend Biotech 获 FDA 批准 LB2501 的 IND 申请","originalTitle","6-K - Legend Biotech Corp (0001801198) (Filer)","summary","Legend Biotech 公布其 LB2501 的 IND 申请获得 FDA 批准，该药物为一种在研的体内 CD19/CD20 双靶点 CAR-T 疗法，用于治疗复发或难治性 B 细胞恶性肿瘤。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-15T12:00:20.000Z","discoveredAt","2026-10-15T12:04:54.910Z","timelineAt","category","ai-products","tags",[80,81,82,83],"stockSymbols",[79],"score",56,"selected",false,"channel","news","story",{"_72":73,"_15":16},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fJdAEbN5yadk",{"_72":73,"_15":16},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","0b2703a9-2b2f-4c8c-a798-7e8dfead5e0a",{"_72":73,"_15":16},"zh","

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: October 15, 2026

Commission File Number: 001-39307

Legend Biotech Corporation
(Translation of registrant's name into English)

77 Corporate Drive
Bridgewater, New Jersey 08807
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

On October 15, 2026, Legend Biotech Corporation (the “Company”) issued a press release announcing clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy for the treatment of relapsed or refractory B-cell malignancies.

This report on Form 6-K, including the exhibits attached hereto, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-278050 and 333-257625) and Form S-8 (Nos. 333-299349, 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

EXHIBIT INDEX

Exhibit		Title

99.1		Press Release dated October 15, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Legend Biotech Corporation
		(Registrant)


Date: October 15, 2026		/s/ Ingrid Zhang
		Ingrid Zhang
		Chief Executive Officer

","zhKind","complete","LEGN","公司与财报","行业与主题","政策与监管","其他","aihot","/items/o7by3aenjuppy7f3mi1rbavaa","https://www.sec.gov/Archives/edgar/data/1801198/000117184326006646/0001171843-26-006646-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]